CIPLA Q2 FY27
Net Profit: βΉ852 Cr β37% YoY | β8% QoQ
Revenue: βΉ7,404 Cr β2% YoY | β4% QoQ
Other Income: βΉ151 Cr vs βΉ269 Cr YoY | βΉ211 Cr QoQ
Operating Profit: βΉ1,388 Cr β27% YoY | β16% QoQ
Operating Profit Margin: 18.7% vs 25.0% YoY | 16.7% QoQ
EPS: βΉ10.86 β35% YoY | β11% QoQ
Net Profit: βΉ852 Cr β37% YoY | β8% QoQ
Revenue: βΉ7,404 Cr β2% YoY | β4% QoQ
Other Income: βΉ151 Cr vs βΉ269 Cr YoY | βΉ211 Cr QoQ
Operating Profit: βΉ1,388 Cr β27% YoY | β16% QoQ
Operating Profit Margin: 18.7% vs 25.0% YoY | 16.7% QoQ
EPS: βΉ10.86 β35% YoY | β11% QoQ
CIPLA Q2 FY27 : ACTUAL VS ESTIMATES
β’ Net Profit: βΉ852 Cr vs βΉ949 Cr est. β MISS BY 10.22% π΄
β’ Revenue: βΉ7,404 Cr vs βΉ7,498 Cr est. β MISS BY 1.25% π΄
β’ EBITDA: βΉ1,388 Cr vs βΉ1,371 Cr est. β BEAT BY 1.24% π’
β’ EBITDA Margin: 18.7% vs 18.3% est. β BEAT BY 40 BPS π’
β’ Net Profit: βΉ852 Cr vs βΉ949 Cr est. β MISS BY 10.22% π΄
β’ Revenue: βΉ7,404 Cr vs βΉ7,498 Cr est. β MISS BY 1.25% π΄
β’ EBITDA: βΉ1,388 Cr vs βΉ1,371 Cr est. β BEAT BY 1.24% π’
β’ EBITDA Margin: 18.7% vs 18.3% est. β BEAT BY 40 BPS π’
BHARAT SEATS Q2 FY27 (STANDALONE)
Net Profit: βΉ15 Cr β54% YoY | β15% QoQ
Revenue: βΉ709 Cr β55% YoY | β23% QoQ
Other Income: βΉ1 Cr vs βΉ3 Cr YoY | βΉ1 Cr QoQ
Operating Profit: βΉ32 Cr β41% YoY | β13% QoQ
Operating Profit Margin: 4.5% vs 4.9% YoY | 4.9% QoQ
EPS: βΉ2.42 β53% YoY | β15% QoQ
Net Profit: βΉ15 Cr β54% YoY | β15% QoQ
Revenue: βΉ709 Cr β55% YoY | β23% QoQ
Other Income: βΉ1 Cr vs βΉ3 Cr YoY | βΉ1 Cr QoQ
Operating Profit: βΉ32 Cr β41% YoY | β13% QoQ
Operating Profit Margin: 4.5% vs 4.9% YoY | 4.9% QoQ
EPS: βΉ2.42 β53% YoY | β15% QoQ
β€1
BHARAT BIJLEE Q2 FY27 (STANDALONE)
β’ Net Profit: βΉ46 Cr β63% YoY | β135% QoQ
β’ Revenue: βΉ736 Cr β55% YoY | β35% QoQ
β’ Operating Profit: βΉ59 Cr β69% YoY | β104% QoQ
β’ Margin: 8.0% vs 7.4% YoY | 5.3% QoQ
β’ EPS: βΉ40.73 β63% YoY | β134% QoQ
β’ Net Profit: βΉ46 Cr β63% YoY | β135% QoQ
β’ Revenue: βΉ736 Cr β55% YoY | β35% QoQ
β’ Operating Profit: βΉ59 Cr β69% YoY | β104% QoQ
β’ Margin: 8.0% vs 7.4% YoY | 5.3% QoQ
β’ EPS: βΉ40.73 β63% YoY | β134% QoQ
KIRLOSKAR PNEUMATIC Q2 FY27
Net Profit: βΉ40 Cr β9% YoY | β20% QoQ
Revenue: βΉ326 Cr β16% YoY | β8% QoQ
Other Income: βΉ8 Cr vs βΉ7 Cr YoY | βΉ8 Cr QoQ
EPS: βΉ3.08 β8% YoY | β20% QoQ
Net Profit: βΉ40 Cr β9% YoY | β20% QoQ
Revenue: βΉ326 Cr β16% YoY | β8% QoQ
Other Income: βΉ8 Cr vs βΉ7 Cr YoY | βΉ8 Cr QoQ
EPS: βΉ3.08 β8% YoY | β20% QoQ
KFIN TECH says
Stick To EBITDA Margin Guidance Of 40-45% For FY27
Stick To EBITDA Margin Guidance Of 40-45% For FY27
β€1
Morepen Laboratories Ltd β RECORD Q2 REVENUE AND EBITDA
Financial results for the quarter and half year ended September 30, 2026:
- Q2 FY27 Revenue: INR 755 Cr, up 81% YoY
- Q2 FY27 EBITDA: INR 132 Cr, up 273% YoY
- Q2 FY27 PAT: INR 89 Cr, up 117% YoY
- Q2 CDMO Revenue: INR 253 Cr (52% of API + CDMO revenue)
- Q2 Exports: INR 397 Cr, up 131% YoY
- Q2 Medical Devices: INR 208 Cr, up 65% YoY
Financial results for the quarter and half year ended September 30, 2026:
- Q2 FY27 Revenue: INR 755 Cr, up 81% YoY
- Q2 FY27 EBITDA: INR 132 Cr, up 273% YoY
- Q2 FY27 PAT: INR 89 Cr, up 117% YoY
- Q2 CDMO Revenue: INR 253 Cr (52% of API + CDMO revenue)
- Q2 Exports: INR 397 Cr, up 131% YoY
- Q2 Medical Devices: INR 208 Cr, up 65% YoY
β€1
BBL: Q2 SL NET PROFIT 460M RUPEES VS 282M (YOY)
BBL: Q2 EBITDA 587M RUPEES VS 348M (YOY); Q2 EBITDA MARGIN 7.98% VS 7.35% (YOY)
BBL: Q2 REVENUE 7.36B RUPEES VS 4.73B (YOY)
BBL: Q2 EBITDA 587M RUPEES VS 348M (YOY); Q2 EBITDA MARGIN 7.98% VS 7.35% (YOY)
BBL: Q2 REVENUE 7.36B RUPEES VS 4.73B (YOY)
RADICO Q2 : STANDALONE NET PROFIT UP 66.2% AT βΉ230.87 CR (YOY), UP 2.2% (QOQ). GOOD (ON 1ST LOOK)
Revenue up 10.4% at βΉ5,582.71 Cr (YOY), down 4.9% (QOQ).
Profit before exceptional items and tax up 65.1% at βΉ307.71 Cr (YOY), up 2.1% (QOQ); no exceptional items in the quarter.
Consolidated net profit up 66.5% at βΉ232.35 Cr (YOY); consolidated revenue up 10.4% at βΉ5,582.71 Cr (YOY).
Standalone EPS βΉ17.23 v βΉ10.38 (YOY); diluted βΉ17.22 v βΉ10.37.
Revenue up 10.4% at βΉ5,582.71 Cr (YOY), down 4.9% (QOQ).
Profit before exceptional items and tax up 65.1% at βΉ307.71 Cr (YOY), up 2.1% (QOQ); no exceptional items in the quarter.
Consolidated net profit up 66.5% at βΉ232.35 Cr (YOY); consolidated revenue up 10.4% at βΉ5,582.71 Cr (YOY).
Standalone EPS βΉ17.23 v βΉ10.38 (YOY); diluted βΉ17.22 v βΉ10.37.
RADICO KHAITAN Q2 FY27 (STANDALONE)
β’ Net Profit: βΉ231 Cr β66% YoY | β2% QoQ
β’ Revenue: βΉ5,583 Cr β10% YoY | β5% QoQ
β’ EBITDA: βΉ357 Cr β50% YoY | β2% QoQ
β’ EBITDA Margin: 6.4% vs 4.7% YoY | 5.9% QoQ
β’ Other Income: βΉ5 Cr
β’ EPS: βΉ17.23 β66% YoY | β2% QoQ
β’ Net Profit: βΉ231 Cr β66% YoY | β2% QoQ
β’ Revenue: βΉ5,583 Cr β10% YoY | β5% QoQ
β’ EBITDA: βΉ357 Cr β50% YoY | β2% QoQ
β’ EBITDA Margin: 6.4% vs 4.7% YoY | 5.9% QoQ
β’ Other Income: βΉ5 Cr
β’ EPS: βΉ17.23 β66% YoY | β2% QoQ
CENTURY ENKA Q2 FY27
β’ Net Profit: βΉ18 Cr β17% YoY | β70% QoQ
β’ Revenue: βΉ558 Cr β37% YoY | β1% QoQ
β’ EBITDA: βΉ33 Cr β4% YoY | β62% QoQ
β’ EBITDA Margin: 5.9% vs 7.7% YoY | 15.5% QoQ
β’ Other Income: βΉ10 Cr
β’ EPS: βΉ8.46 β17% YoY | β70% QoQ
β’ Net Profit: βΉ18 Cr β17% YoY | β70% QoQ
β’ Revenue: βΉ558 Cr β37% YoY | β1% QoQ
β’ EBITDA: βΉ33 Cr β4% YoY | β62% QoQ
β’ EBITDA Margin: 5.9% vs 7.7% YoY | 15.5% QoQ
β’ Other Income: βΉ10 Cr
β’ EPS: βΉ8.46 β17% YoY | β70% QoQ
RADICO KHAITAN: NET DEBT-FREE TARGET DELAYED TO H2 FY2027 FROM EARLIER Q2 FY2027 GUIDANCE, DESPITE βΉ68.7 CR REDUCTION IN NET DEBT SINCE MARCH 31, 2026.
RADICO: Q2 EBITDA 3.57B RUPEES VS 2.38B (YOY); Q2 EBITDA MARGIN 20.47% VS 15.91% (YOY) - EXCLUDING EXCISE DUTY
MANBA FINANCE Q2 FY27 (STANDALONE)
β’ Net Profit: βΉ14 Cr β20% YoY | β4% QoQ
β’ NII: βΉ52 Cr β41% YoY | β25% QoQ
β’ PPOP: βΉ30 Cr β45% YoY | β24% QoQ
β’ Provisions: βΉ8 Cr β53% YoY | β1% QoQ
β’ Loan Assets: βΉ1,634 Cr
β’ EPS: βΉ2.73 vs βΉ2.27 YoY | βΉ2.64 QoQ
β’ Net Profit: βΉ14 Cr β20% YoY | β4% QoQ
β’ NII: βΉ52 Cr β41% YoY | β25% QoQ
β’ PPOP: βΉ30 Cr β45% YoY | β24% QoQ
β’ Provisions: βΉ8 Cr β53% YoY | β1% QoQ
β’ Loan Assets: βΉ1,634 Cr
β’ EPS: βΉ2.73 vs βΉ2.27 YoY | βΉ2.64 QoQ
RadicoKhaitan reports its Q2 earnings:
β©Upgrade Our P&A Volume Growth Guidance To 30%
β©Reiterate EBITDA Margin Guidance Of Around 20% For FY27
β©Despite Challenging External Environment, Momentum Across Our Portfolio Gives Us Confidence
β©Upgrade Our P&A Volume Growth Guidance To 30%
β©Reiterate EBITDA Margin Guidance Of Around 20% For FY27
β©Despite Challenging External Environment, Momentum Across Our Portfolio Gives Us Confidence
HUHTAMAKI INDIA Q3 CY26
β’ Net Profit: βΉ29.73 Cr β19.15% YoY | β32.02% QoQ
β’ Revenue: βΉ768.84 Cr β23.07% YoY | β2.51% QoQ
β’ EBITDA: βΉ59.71 Cr β7.62% YoY | β20.53% QoQ
β’ EBITDA Margin: 7.77% vs 8.88% YoY | 10.02% QoQ
β’ Net Profit: βΉ29.73 Cr β19.15% YoY | β32.02% QoQ
β’ Revenue: βΉ768.84 Cr β23.07% YoY | β2.51% QoQ
β’ EBITDA: βΉ59.71 Cr β7.62% YoY | β20.53% QoQ
β’ EBITDA Margin: 7.77% vs 8.88% YoY | 10.02% QoQ